Scrip's Five Must-Know Things - Mar.16, 2026

March 16, 2026

14 min episode · 2 min read

Episode

14 min

Read time

2 min

AI-Generated Summary

Published Mar 17, 2026

Key Takeaways

✓Roche Pipeline Risk: Giadestrant failed the PERSEVERA trial's primary endpoint in first-line ER-positive, HER2-negative advanced breast cancer despite enrolling 992 patients. Jefferies flagged the trial as underpowered. FDA acceptance remains limited to the narrower ESR1-mutated population, constraining peak sales well below Roche's $10B target.
✓BioNTech Leadership Vacuum: Founders Ugur Sahin and Ozlem Tureci are departing to launch an mRNA spinoff, leaving BioNTech without its core visionaries as 15-plus phase three oncology trials approach readout. The company retains €17.2B in cash and a key BMS-partnered PDL1/VEGF bispecific, pemetimaig, as its lead asset.
✓Ipsen Safety-Driven Withdrawal: Tazverik, the only EZH2 inhibitor approved for follicular lymphoma and epithelioid sarcoma, is being voluntarily withdrawn globally after secondary hematologic malignancies emerged in the confirmatory SYMPHONY-1 trial. Sales had already declined 14% to €40.6M in 2025 before the safety signal surfaced.
✓UCB Competitive Positioning: Bimzelx demonstrated statistically significant superiority over AbbVie's Skyrizi at ACR50 week 16 in the 553-patient BE BOLD head-to-head psoriatic arthritis trial. This is UCB's fourth head-to-head superiority win, reinforcing Bimzelx's positioning across rheumatology and dermatology with €2.3B in 2025 annual sales.

What It Covers

Five biotech and pharma developments from the week of March 13, 2026: Roche's Giadestrant phase three failure, BioNTech's founders departing, Ipsen withdrawing Tazverik, Bayer's mixed earnings, and UCB's Bimzelx beating Skyrizi in psoriatic arthritis.

Key Questions Answered

•Roche Pipeline Risk: Giadestrant failed the PERSEVERA trial's primary endpoint in first-line ER-positive, HER2-negative advanced breast cancer despite enrolling 992 patients. Jefferies flagged the trial as underpowered. FDA acceptance remains limited to the narrower ESR1-mutated population, constraining peak sales well below Roche's $10B target.
•BioNTech Leadership Vacuum: Founders Ugur Sahin and Ozlem Tureci are departing to launch an mRNA spinoff, leaving BioNTech without its core visionaries as 15-plus phase three oncology trials approach readout. The company retains €17.2B in cash and a key BMS-partnered PDL1/VEGF bispecific, pemetimaig, as its lead asset.
•Ipsen Safety-Driven Withdrawal: Tazverik, the only EZH2 inhibitor approved for follicular lymphoma and epithelioid sarcoma, is being voluntarily withdrawn globally after secondary hematologic malignancies emerged in the confirmatory SYMPHONY-1 trial. Sales had already declined 14% to €40.6M in 2025 before the safety signal surfaced.
•UCB Competitive Positioning: Bimzelx demonstrated statistically significant superiority over AbbVie's Skyrizi at ACR50 week 16 in the 553-patient BE BOLD head-to-head psoriatic arthritis trial. This is UCB's fourth head-to-head superiority win, reinforcing Bimzelx's positioning across rheumatology and dermatology with €2.3B in 2025 annual sales.

Notable Moment

Bayer's two growth drugs, Nubeqa and Korindia, grew combined sales 67% year-on-year yet represent only 8% of group revenue, while loss-of-exclusivity products Xarelto and Eylea, comprising 11% of sales, fell 28%, mathematically overwhelming the growth story.

Know someone who'd find this useful?